Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Acquisitions (2019)

X4 Pharmaceuticals' Acquisitions history spans 1 years, with the latest figure at $52.8 million for Q4 2019.

  • For Q4 2019, Acquisitions changed N/A year-over-year to $52.8 million; the TTM value through Sep 2020 reached $52.8 million, up 300.0%, while the annual FY2019 figure was $26.4 million, N/A changed from the prior year.
  • Acquisitions reached $52.8 million in Q4 2019 per XFOR's latest filing, up from -$26.4 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $52.8 million in Q4 2019 to a low of -$26.4 million in Q1 2019.